Evidence map›Paper›PMID 19236710›Full record

ArticleBMC molecular biology2009

Genetic correction of splice site mutation in purified and enriched myoblasts isolated from mdx5cv mice.

Katie Maguire, Takayuki Suzuki, Darlise DiMatteo, Hetal Parekh-Olmedo, Eric Kmiec

Open access · hybridAbstract read
In one paragraph

Article in BMC molecular biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Recent advances in Duchenne muscular dystrophy.Degenerative neurological and neuromuscular disease · 2012
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Katie MaguireDepartment of Biological Sciences, University of Delaware, Newark, DE 19716, USA. katie_maguire78@yahoo.com
Takayuki Suzuki
Darlise DiMatteo
Hetal Parekh-Olmedo
Eric Kmiec
University of Delaware · US

Funding

Selectable Gene Editing for Muscular DystrophyR21NS053608 · NINDS · UNIVERSITY OF DELAWARE · PI KMIEC, ERIC B · 2006 to 2007
$268k
NINDS NIH HHS R21 NS053608
6 · The paper itself

Abstract

backgroundDuchenne Muscular Dystrophy (DMD) is an X-linked genetic disorder that results in the production of a dysfunctional form of the protein, dystrophin. The mdx5cv mouse is a model of DMD in which a point mutation in exon 10 of the dystrophin gene creates an artificial splice site. As a result, a 53 base pair deletion of exon 10 occurs with a coincident creation of a frameshift and a premature stop codon. Using primary myoblasts from mdx5cv mice, single-stranded DNA oligonucleotides were designed to correct this DNA mutation.

resultsSingle-stranded DNA oligonucleotides that were designed to repair this splice site mutation corrected the mutation in the gene and restored expression of wild-type dystrophin. This repair was validated at the DNA, RNA and protein level. We also report that the frequency of genetic repair of the mdx mutation can be enhanced if RNAi is used to suppress expression of the recombinase inhibitor protein Msh2 in cultures containing myoblasts but not in those heavily enriched in myoblasts.

conclusionExogenous manipulations, such as RNAi, are certainly feasible and possibly required to increase the successful application of gene repair in some primary or progenitor muscle cells.

Indexed as

AnimalsCells, CulturedGene Knockdown TechniquesMaleMiceMice, Inbred mdxMuscular Dystrophy, DuchenneMutationMutS Homolog 2 ProteinMyoblastsRNA InterferenceRNA Splice SitesTargeted Gene RepairMsh2 protein, mouseMutS Homolog 2 ProteinRNA Splice Sites

Identifiers

PMID19236710
PMCPMC2654480
OpenAlexW2026533332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.